Wuhan Hvsen Biotechnology Co Ltd (300871) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Wuhan Hvsen Biotechnology Co Ltd (300871) has a cash flow conversion efficiency ratio of 0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥59.06 Million ≈ $8.64 Million USD) by net assets (CN¥2.12 Billion ≈ $309.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Wuhan Hvsen Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Wuhan Hvsen Biotechnology Co Ltd (300871) total liabilities for a breakdown of total debt and financial obligations.
Wuhan Hvsen Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wuhan Hvsen Biotechnology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OCI NV
AS:OCI
|
-0.021x |
|
Gokul Agro Resources Limited
NSE:GOKULAGRO
|
0.069x |
|
Vor Biopharma Inc
NASDAQ:VOR
|
0.139x |
|
WELL Health Technologies Corp
TO:WELL
|
0.090x |
|
LOGAN GROUP HD -10
F:5LP
|
N/A |
|
Nexpoint Residential Trust Inc
NYSE:NXRT
|
0.020x |
|
Shanghai Amarsoft Information & Technolgy Co Ltd
SHE:300380
|
-0.059x |
|
Zhejiang Starry Pharm Co Ltd
SHG:603520
|
0.004x |
Annual Cash Flow Conversion Efficiency for Wuhan Hvsen Biotechnology Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Wuhan Hvsen Biotechnology Co Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.47 Billion ≈ $214.41 Million |
CN¥43.53 Million ≈ $6.37 Million |
0.030x | -51.74% |
| 2023-12-31 | CN¥1.51 Billion ≈ $220.86 Million |
CN¥92.92 Million ≈ $13.60 Million |
0.062x | -1.84% |
| 2022-12-31 | CN¥1.54 Billion ≈ $225.56 Million |
CN¥96.68 Million ≈ $14.15 Million |
0.063x | -34.79% |
| 2021-12-31 | CN¥1.62 Billion ≈ $236.89 Million |
CN¥155.72 Million ≈ $22.79 Million |
0.096x | +174.38% |
| 2020-12-31 | CN¥1.38 Billion ≈ $201.81 Million |
CN¥48.35 Million ≈ $7.08 Million |
0.035x | -87.40% |
| 2019-12-31 | CN¥378.28 Million ≈ $55.35 Million |
CN¥105.24 Million ≈ $15.40 Million |
0.278x | +327.97% |
| 2018-12-31 | CN¥324.52 Million ≈ $47.49 Million |
CN¥21.10 Million ≈ $3.09 Million |
0.065x | -82.00% |
| 2017-12-31 | CN¥223.11 Million ≈ $32.65 Million |
CN¥80.56 Million ≈ $11.79 Million |
0.361x | -6.91% |
| 2016-12-31 | CN¥154.70 Million ≈ $22.64 Million |
CN¥60.00 Million ≈ $8.78 Million |
0.388x | -- |
About Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various vet… Read more